PRESS RELEASE
Jerini reorganizes its peptide technologies
business unit
Berlin/Germany, July 15, 2004. – Jerini has transferred
its peptide technologies business unit to a wholly-owned subsidiary
to ensure further growth and increased market penetration. Under
the direction of former business unit head Dr. Holger Wenschuh
the business will be continued as JPT Peptide Technologies GmbH.
JPT provides peptide-based products and services whereas Jerini
AG will focus on drug discovery and development. The new subsidiary
will improve its market visi-bility as a fee-for-service provider
and will be able to react even faster than today to market development
and customer needs thus enhancing marketability of their products.
JPT Peptide Technologies GmbH has taken over all employees, production
facilities, intellectual property, and contractual obligations
related to the former business unit. The new subsidiary continues
its strategy to provide and develop innovative peptide-based services
and products for biomedical research. „The foundation of
an independent company facilitates our strategic development towards
a unique outsourcing partner for pharmaceutical companies”,
said Holger Wenschuh, Managing Director of JPT, adding, „our
main efforts will be related to the further development and provision
of high-content peptide tools for signal transduction research,
immunology and high-throughput screening.”
About Jerini
Jerini AG is a drug discovery and development company based in
Berlin, Germany. The company has built a pipeline of several preclinical
and two clinical projects (phase II) with its proprietary Peptides-To-Drugs
(P2D) discovery platform. The company’s lead molecule Icatibant,
a highly potent and specific peptidomimetic bradykinin B2 receptor
antagonist is entering pivotal registration trials in the third
quarter of this year in the indication Angioedema. P2D was developed
by the company to address extra- and intra-cellular targets and
to overcome the limitations of conventional HTS or protein-based
discovery approaches. Jerini’s wholly-owned subsidiary, JPT
Peptide Technologies GmbH (“JPT”), provides innovative
peptide-related services for all fields of biomedical research.
For questions, please contact:
Helena Dreznjak
Corporate Communications Manager
Jerini AG
Invalidenstr. 130
10115 Berlin/Germany
T + 49 - 30 - 97893 – 118
X + 49 - 30 - 97893 – 105
www.jerini.com
|
